tapebrief

UHS · Q2 2025 Earnings

Cautious

Universal Health Services

Reported July 29, 2025

30-second summary

UHS lifted FY25 revenue, EBITDA, and EPS guides on the back of a newly approved Tennessee Medicaid supplemental payment program and first-half operating momentum, with Q2 revenue up 9.6% to $4.28B and adjusted EBITDA margin net of NCI at 15.0%. The headline tension: management quantified the One Big Beautiful Bill drag at $360–400M annual net benefit reduction by 2032, against $1.2B of current annual net benefit from state supplemental programs — a ~30% bite, phased in starting 2028. Behavioral pricing is doing the heavy lifting (+8.6% revenue per adjusted admission same-facility) while volume (+0.4% admissions) continues to disappoint, and Cedar Hill is bleeding $50M of EBITDA in 2025 while it waits on Medicare certification.

Headline numbers

EPS

Q2 FY2025

$5.35

Revenue

Q2 FY2025

$4.28B

+9.6% YoY

Operating margin

Q2 FY2025

11.7%

Key financials

Q2 FY2025
MetricQ2 FY2025YoY
Revenue$4.28B+9.6%
EPS$5.35—
Operating margin11.7%—

Guidance

Prior quarter data unavailable — comparison not possible.

Segment KPIs

Q2 FY2025
SegmentQ2 FY2025YoY
Acute Care Hospital Services$2.401B+10.2%
Behavioral Health Care Services$1.883B+8.9%

Other KPIs

Q2 FY2025
SegmentQ2 FY2025
Acute Care Adjusted Admissions (same facility)+2.0%
Acute Care Adjusted Patient Days (same facility)+1.1%
Acute Care Revenue per Adjusted Admission (same facility)+3.8%
Behavioral Health Adjusted Admissions (same facility)+0.4%
Behavioral Health Adjusted Patient Days (same facility)+1.2%
Behavioral Health Revenue per Adjusted Admission (same facility)+8.6%
Adjusted EBITDA margin net of NCI15.0%
Days Sales Outstanding50 days

Management tone

The Q&A makes clear that the One Big Beautiful Bill has become the dominant strategic frame even as 2025 numbers move higher. Management quantified the headwind ($360–400M annual net reduction by 2032 against $1.2B of current annual supplemental program benefit) and pivoted immediately to mitigation: non-Medicaid-centric behavioral programs, new DPPs in other states, legislative engagement, and pandemic-era cost flexibility as proof of adaptability. The tone is not defensive — it's deliberate.

Behavioral volume continues to be the open wound. Pricing has now outperformed the 4–5% model two quarters running while volume runs at 0.4–1.2%, and management was direct in Q&A that volume "is opportunity area." The new outpatient buildout — 10–15 freestanding facilities annually at ~$1M each, targeting both step-down (post-inpatient) and step-in (avoiding inpatient stigma) patient populations — is the most concrete capacity initiative articulated. Whether it moves the 2.5–3% adjusted patient day target into reach is the test.

Cedar Hill received unusually granular disclosure: $50M of 2025 EBITDA drag, Joint Commission survey "imminent," D.C. agreed to pay retroactive to the deemed-ready date, and 12–18 months post-certification to divisional profitability. The specificity suggests management wants the Street to model this as a discrete, sized event rather than an open-ended drag.

AI commentary was substantive but unquantified — denial management/appeals, post-discharge follow-up calls, clinical workflow. Framed as an offset lever for the 2028+ DPP reductions, not a 2025 P&L story.

Q&A highlights

Pito Chikurin · Doce Bank

Clarification on the $360-400M net impact from the One Beautiful Bill in 2032 and management's views on offsetting impacts, core growth rates, and strategic adjustments.

Management acknowledged the reductions don't begin materially until 2028, providing time for strategic pivots. Noted opportunities include shifting to non-Medicaid-centric behavioral programs, potential new DPP programs, and possible legislative changes. Emphasized ability to adapt based on pandemic response experience with rapid headcount and capital spending reductions.

$360-400M annual net benefit reduction by 2032Reductions commence 2028 state fiscal years5-year phase-in through 2032Current $1.2B annual net benefit from approved state Medicaid supplemental programs

Andrew Moffat · Barkley

Update on Cedar Hill Regional Medical Center's Medicare certification status, quantified startup losses, and ramp to mature profitability timeline.

Cedar Hill experienced $25M EBITDA drag in Q2 with another $25M expected in H2 2025. Joint Commission Survey expected imminently (this week or next). Medicare certification delays were the primary issue, not demand. D.C. agreed to pay back to when deemed ready for certification. Once certified, facility will build surgical/procedural volumes. Expected to reach divisional-wide profitability by 2026 after 12-18 months of additional operations.

$25M Q2 EBITDA loss$25M additional H2 2025 dragJoint Commission Survey imminentEmergency room volumes described as 'quite busy and encouraging'

Jason Casola · Guggenheim

Strategic pathway to capturing larger share of behavioral outpatient market, given low leverage ratio and planned de novo builds.

Management outlined two outpatient revenue streams: (1) step-down business from inpatient discharges into intensive outpatient/partial hospitalization programs, with focus on improving patient retention; (2) step-in business via freestanding outpatient facilities not on hospital campuses to attract patients uncomfortable with inpatient facility experience. Plan to open 10-15 freestanding facilities annually requiring ~$1M capital per facility with focus on therapist staffing and patient flow.

10-15 new outpatient facilities annually planned~$1M average capital per outpatient facilityFocus on step-down and step-in patient populationsFreestanding facilities in leased storefront settings

Benjamin Rossi · JPMorgan

Behavioral pricing outperformance breakdown (rates vs. acuity vs. supplemental payments) and guidance contemplation for volume growth targets.

Excluding Tennessee DPP impact, behavioral revenue grew 5.4% with 4.2% pricing increase and 1.2% adjusted patient day increase (vs. original 4-5% pricing guidance). Confirmed 4-5% pricing is sustainable intermediate-term growth rate. Acknowledged 1.2% volume growth is opportunity area, particularly on outpatient side where focus has intensified.

5.4% total revenue growth (ex-Tennessee DPP)4.2% pricing increase achieved1.2% adjusted patient day increase4-5% sustainable pricing growth assumption

Craig Hattenbach · Morgan Stanley

Long-term behavioral revenue growth model normalization and potential AI/technology offsets to DPP headwinds.

Reaffirmed 6-8% (7% midpoint) long-term behavioral revenue growth model composed of 4-5% price and 0.5-3% volume. Acknowledged pricing has outperformed while volume lags. Management exploring AI applications in denial management/appeals, post-discharge patient follow-up, and clinical workflow optimization. Early patient feedback positive on AI-driven follow-up calls.

6-8% long-term revenue growth target (7% midpoint)4-5% pricing component, 0.5-3% volume componentAI experiments in denial management and post-discharge follow-upAI deployed for revenue cycle efficiency and clinical productivity

What to watch into next quarter

Cedar Hill Joint Commission survey outcome and Medicare certification date. Management said the survey was "imminent" as of late July. Resolution this quarter would convert a $50M 2025 EBITDA drag into a 2026 profitability story; further delay extends the drag.

Behavioral same-facility adjusted patient days. Q2 came in at +1.2%; the long-term model requires 0.5–3% and management's internal target sits at 2.5–3%. Watch for any quarter where volume moves above +2% as the first sign the outpatient buildout is gaining traction.

Behavioral pricing ex-Tennessee DPP. Q2 ran at +4.2% ex-Tennessee. Management called 4–5% the sustainable rate; watch whether ex-DPP pricing holds above 4% or drops toward 3% as commercial mix and acuity normalize.

Additional state DPP program approvals. Tennessee drove this quarter's guide raise. Management cited new DPPs as a primary offset lever to the 2028 reductions — track approvals from other states where UHS operates.

FY25 guide trajectory at Q3. Current FY25 midpoints: revenue $17.20B, EBITDA $2.50B, EPS $20.50. Watch whether Q3 brings another raise (signaling Tennessee tailwind plus operating leverage) or just maintenance.

Sources

  1. UHS Q2-2025 press release, exhibit 99.1: https://www.sec.gov/Archives/edgar/data/352915/000095017025099405/uhs-ex99_1.htm
  2. UHS Q2-2025 earnings conference call Q&A (transcript excerpts cited above)

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.